Literature DB >> 34549974

Asymmetric Structures and Conformational Plasticity of the Uncleaved Full-Length Human Immunodeficiency Virus Envelope Glycoprotein Trimer.

Shijian Zhang1,2, Kunyu Wang3, Wei Li Wang1,3,4, Hanh T Nguyen1,2, Shuobing Chen3, Maolin Lu5, Eden P Go6, Haitao Ding7, Robert T Steinbock1, Heather Desaire6, John C Kappes7,8, Joseph Sodroski1,2,9, Youdong Mao1,3,4.   

Abstract

The functional human immunodeficiency virus (HIV-1) envelope glycoprotein (Env) trimer [(gp120/gp41)3] is produced by cleavage of a conformationally flexible gp160 precursor. gp160 cleavage or the binding of BMS-806, an entry inhibitor, stabilizes the pretriggered, "closed" (state 1) conformation recognized by rarely elicited broadly neutralizing antibodies. Poorly neutralizing antibodies (pNAbs) elicited at high titers during natural infection recognize more "open" Env conformations (states 2 and 3) induced by binding the receptor, CD4. We found that BMS-806 treatment and cross-linking decreased the exposure of pNAb epitopes on cell surface gp160; however, after detergent solubilization, cross-linked and BMS-806-treated gp160 sampled non-state-1 conformations that could be recognized by pNAbs. Cryo-electron microscopy of the purified BMS-806-bound gp160 revealed two hitherto unknown asymmetric trimer conformations, providing insights into the allosteric coupling between trimer opening and structural variation in the gp41 HR1N region. The individual protomer structures in the asymmetric gp160 trimers resemble those of other genetically modified or antibody-bound cleaved HIV-1 Env trimers, which have been suggested to assume state-2-like conformations. Asymmetry of the uncleaved Env potentially exposes surfaces of the trimer to pNAbs. To evaluate the effect of stabilizing a state-1-like conformation of the membrane Env precursor, we treated cells expressing wild-type HIV-1 Env with BMS-806. BMS-806 treatment decreased both gp160 cleavage and the addition of complex glycans, implying that gp160 conformational flexibility contributes to the efficiency of these processes. Selective pressure to maintain flexibility in the precursor of functional Env allows the uncleaved Env to sample asymmetric conformations that potentially skew host antibody responses toward pNAbs. IMPORTANCE The envelope glycoprotein (Env) trimers on the surface of human immunodeficiency virus (HIV-1) mediate the entry of the virus into host cells and serve as targets for neutralizing antibodies. The functional Env trimer is produced by cleavage of the gp160 precursor in the infected cell. We found that the HIV-1 Env precursor is highly plastic, allowing it to assume different asymmetric shapes. This conformational plasticity is potentially important for Env cleavage and proper modification by sugars. Having a flexible, asymmetric Env precursor that can misdirect host antibody responses without compromising virus infectivity would be an advantage for a persistent virus like HIV-1.

Entities:  

Keywords:  Env; antibody; asymmetry; cleavage; conformation; cryo-electron microscopy; furin; processing; structure

Mesh:

Substances:

Year:  2021        PMID: 34549974      PMCID: PMC8610584          DOI: 10.1128/JVI.00529-21

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  138 in total

1.  Transfer of endoplasmic reticulum and Golgi retention signals to human immunodeficiency virus type 1 gp160 inhibits intracellular transport and proteolytic processing of viral glycoprotein but does not influence the cellular site of virus particle budding.

Authors:  T Pfeiffer; H Zentgraf; B Freyaldenhoven; V Bosch
Journal:  J Gen Virol       Date:  1997-07       Impact factor: 3.891

2.  CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5.

Authors:  A Trkola; T Dragic; J Arthos; J M Binley; W C Olson; G P Allaway; C Cheng-Mayer; J Robinson; P J Maddon; J P Moore
Journal:  Nature       Date:  1996-11-14       Impact factor: 49.962

3.  The impact of envelope glycoprotein cleavage on the antigenicity, infectivity, and neutralization sensitivity of Env-pseudotyped human immunodeficiency virus type 1 particles.

Authors:  Carolina Herrera; Per Johan Klasse; Elizabeth Michael; Shivani Kake; Kelly Barnes; Christopher W Kibler; Lila Campbell-Gardener; Zhihai Si; Joseph Sodroski; John P Moore; Simon Beddows
Journal:  Virology       Date:  2005-07-20       Impact factor: 3.616

4.  Specific amino acids in the N-terminus of the gp41 ectodomain contribute to the stabilization of a soluble, cleaved gp140 envelope glycoprotein from human immunodeficiency virus type 1.

Authors:  Antu K Dey; Kathryn B David; Per J Klasse; John P Moore
Journal:  Virology       Date:  2006-11-07       Impact factor: 3.616

5.  Distinct mechanisms regulate exposure of neutralizing epitopes in the V2 and V3 loops of HIV-1 envelope.

Authors:  Chitra Upadhyay; Luzia M Mayr; Jing Zhang; Rajnish Kumar; Miroslaw K Gorny; Arthur Nádas; Susan Zolla-Pazner; Catarina E Hioe
Journal:  J Virol       Date:  2014-08-27       Impact factor: 5.103

6.  Cleavage strongly influences whether soluble HIV-1 envelope glycoprotein trimers adopt a native-like conformation.

Authors:  Rajesh P Ringe; Rogier W Sanders; Anila Yasmeen; Helen J Kim; Jeong Hyun Lee; Albert Cupo; Jacob Korzun; Ronald Derking; Thijs van Montfort; Jean-Philippe Julien; Ian A Wilson; Per Johan Klasse; Andrew B Ward; John P Moore
Journal:  Proc Natl Acad Sci U S A       Date:  2013-10-21       Impact factor: 11.205

7.  Dual Pathways of Human Immunodeficiency Virus Type 1 Envelope Glycoprotein Trafficking Modulate the Selective Exclusion of Uncleaved Oligomers from Virions.

Authors:  Shijian Zhang; Hanh T Nguyen; Haitao Ding; Jia Wang; Shitao Zou; Lihong Liu; Debjani Guha; Dana Gabuzda; David D Ho; John C Kappes; Joseph Sodroski
Journal:  J Virol       Date:  2021-01-13       Impact factor: 5.103

8.  HIV-1 Env trimer opens through an asymmetric intermediate in which individual protomers adopt distinct conformations.

Authors:  Xiaochu Ma; Maolin Lu; Jason Gorman; Daniel S Terry; Xinyu Hong; Zhou Zhou; Hong Zhao; Roger B Altman; James Arthos; Scott C Blanchard; Peter D Kwong; James B Munro; Walther Mothes
Journal:  Elife       Date:  2018-03-21       Impact factor: 8.140

9.  Limited neutralizing antibody specificities drive neutralization escape in early HIV-1 subtype C infection.

Authors:  Penny L Moore; Nthabeleng Ranchobe; Bronwen E Lambson; Elin S Gray; Eleanor Cave; Melissa-Rose Abrahams; Gama Bandawe; Koleka Mlisana; Salim S Abdool Karim; Carolyn Williamson; Lynn Morris
Journal:  PLoS Pathog       Date:  2009-09-18       Impact factor: 6.823

10.  Subunit organization of the membrane-bound HIV-1 envelope glycoprotein trimer.

Authors:  Youdong Mao; Liping Wang; Christopher Gu; Alon Herschhorn; Shi-Hua Xiang; Hillel Haim; Xinzhen Yang; Joseph Sodroski
Journal:  Nat Struct Mol Biol       Date:  2012-08-05       Impact factor: 15.369

View more
  3 in total

1.  Global Increases in Human Immunodeficiency Virus Neutralization Sensitivity Due to Alterations in the Membrane-Proximal External Region of the Envelope Glycoprotein Can Be Minimized by Distant State 1-Stabilizing Changes.

Authors:  Qian Wang; Florian Esnault; Meiqing Zhao; Ta-Jung Chiu; Amos B Smith; Hanh T Nguyen; Joseph G Sodroski
Journal:  J Virol       Date:  2022-03-15       Impact factor: 6.549

2.  Temsavir Treatment of HIV-1-Infected Cells Decreases Envelope Glycoprotein Recognition by Broadly Neutralizing Antibodies.

Authors:  Marianne Boutin; Dani Vézina; Shilei Ding; Jérémie Prévost; Annemarie Laumaea; Lorie Marchitto; Sai Priya Anand; Halima Medjahed; Gabrielle Gendron-Lepage; Catherine Bourassa; Guillaume Goyette; Andrew Clark; Jonathan Richard; Andrés Finzi
Journal:  mBio       Date:  2022-04-27       Impact factor: 7.786

3.  HIV-1 Envelope Glycoproteins Proteolytic Cleavage Protects Infected Cells from ADCC Mediated by Plasma from Infected Individuals.

Authors:  Jérémie Prévost; Halima Medjahed; Dani Vézina; Hung-Ching Chen; Beatrice H Hahn; Amos B Smith; Andrés Finzi
Journal:  Viruses       Date:  2021-11-06       Impact factor: 5.818

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.